Acorda Therapeutics, Inc. (NASDAQ:ACOR) has received an average rating of “Hold” from the nineteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $21.47.
Several analysts recently weighed in on the company. Janney Montgomery Scott reissued a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a report on Wednesday, August 30th. ValuEngine raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Piper Jaffray Companies reissued a “neutral” rating and set a $22.00 price target on shares of Acorda Therapeutics in a report on Tuesday. J P Morgan Chase & Co set a $24.00 price target on Acorda Therapeutics and gave the stock a “hold” rating in a report on Tuesday, October 31st. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a report on Tuesday, October 31st.
A number of institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in Acorda Therapeutics during the 3rd quarter worth $541,000. Convergence Investment Partners LLC bought a new position in Acorda Therapeutics during the 3rd quarter worth $1,294,000. OxFORD Asset Management LLP bought a new position in Acorda Therapeutics during the 3rd quarter worth $2,025,000. KBC Group NV increased its stake in Acorda Therapeutics by 194.3% during the 3rd quarter. KBC Group NV now owns 64,007 shares of the biopharmaceutical company’s stock worth $1,514,000 after acquiring an additional 42,256 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Acorda Therapeutics by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock worth $62,813,000 after acquiring an additional 283,091 shares during the period.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business had revenue of $141.07 million during the quarter, compared to analyst estimates of $150.64 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The business’s quarterly revenue was up 4.0% on a year-over-year basis. equities research analysts anticipate that Acorda Therapeutics will post -0.07 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Acorda Therapeutics, Inc. (ACOR) Given Consensus Recommendation of “Hold” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/acorda-therapeutics-inc-acor-given-consensus-recommendation-of-hold-by-brokerages.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.